Antigenicity studies in humans and immunogenicity studies in mice: an MSP1P subdomain as a candidate for malaria vaccine development

The newly identified GPI-anchored Plasmodium vivax merozoite surface protein 1 paralog (MSP1P) has a highly antigenic C-terminus that binds erythrocytes. To characterize the antigenicity and immunogenicity of two regions (PvMSP1P-19 and -33) of the highly conserved C-terminus of MSP1P relative to Pv...

Full description

Saved in:
Bibliographic Details
Published in:Microbes and infection 2014-05, Vol.16 (5), p.419-428
Main Authors: Cheng, Yang, Shin, Eun-Hee, Lu, Feng, Wang, Bo, Choe, Jongseon, Tsuboi, Takafumi, Han, Eun-Taek
Format: Article
Language:English
Subjects:
Adolescent
Adult
Animals
Antibodies, Protozoan - blood
Child
Cytokines
Cytokines - secretion
Female
Humans
IgG subclasses
Immunogenicity
Immunoglobulin G - blood
Malaria Vaccines - immunology
Malaria Vaccines - isolation & purification
Malaria, Vivax - prevention & control
Male
Merozoite Surface Protein 1 - immunology
Mice, Inbred BALB C
Middle Aged
MSP1P
Plasmodium vivax
Plasmodium vivax - immunology
Th1 Cells - immunology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The newly identified GPI-anchored Plasmodium vivax merozoite surface protein 1 paralog (MSP1P) has a highly antigenic C-terminus that binds erythrocytes. To characterize the antigenicity and immunogenicity of two regions (PvMSP1P-19 and -33) of the highly conserved C-terminus of MSP1P relative to PvMSP1-19, 30 P. vivax malaria-infected patients and two groups of mice (immunized with PvMSP1P-19 or -33) were tested for IgG subclass antibodies against PvMSP1P-19 and -33 antigens. In the patients infected with P. vivax, IgG1 and IgG3 levels were significantly higher than those levels in healthy individuals, and were the predominant response to the two C-terminal fragments of PvMSP1P (p 
ISSN:1286-4579
1769-714X
DOI:10.1016/j.micinf.2014.02.002